London +4420 814 42225
Moscow +7495 543 9194
Kiev +38044 599 2950

Our Clients

Order Informer

Home > News >

Halix to provide drug substance for AstraZeneca COVID-19 vaccine candidate

December 09/2020

MOSCOW (MRC) -- Halix (Leiden, Netherlands), a biopharmaceutical contract development and manufacturing organization (CDMO), says it has signed an agreement with AstraZeneca to provide large-scale commercial manufacturing of drug substance AZD1222 for the COVID-19 vaccine candidate co-invented by the University of Oxford, UK, and its spin-out company Vaccitech, said Chemweek.

Halix says it has expanded production at its 6,700 square-meter current good manufacturing practice (cGMP) facility at the Bio Science Park at Leiden with two additional viral vector production lines, to meet the increased demand.

Halix continues its role as one of the original partners in the University of Oxfords consortium for the manufacture of AZD1222, the company says. Through the consortium, the partners are bringing their collective expertise and manufacturing capabilities to support vaccine production and combat this evolving crisis, says Alex Huybens, COO at Halix.

As MRC informed earlier, Wacker will support production of CureVacs COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.

As MRC reported earlier, Wacker Chemie operates a 90 ktpa EVA compounding plant at the Ulsan site, consisting of two lines. The second line with a capacity of 40 thousand tons of products per year was launched in 2013.

According to MRC's DataScope, September EVA imports to Russia fell by 30,32% year on year to 2,38 tonnes from 3,420 tonnes a year earlier, and overall imports of this grade of ethylene copolymer into the Russian Federation dropped in January-September 2020 by 9,85% year on year to 26,340 tonnes (29,220 tonnes a year earlier).
Author:Anna Larionova
Tags:petroleum products, crude oil, EVA, neftegaz, petrochemistry, Wacker, COVID-19.
Category:General News
| More

Leave a comment

MRC help


 All News   News subscribe